Michalski, Kerstin
Schlötelburg, Wiebke
Hartrampf, Philipp
Heinrich, Marieke
Serfling, Sebastian
Buck, Andreas K.
Werner, Rudolf A.
Kosmala, Aleksander
Weich, Alexander
Funding for this research was provided by:
Bavarian Cancer Research Center
Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (Z-2/91)
Universitätsklinikum Würzburg
Article History
Received: 8 December 2023
Revised: 25 January 2024
Accepted: 27 January 2024
First Online: 8 February 2024
Declarations
:
: Kerstin Michalski has received speaker honoraria from Novartis. Rudolf A. Werner has received speaker honoraria from PentixaPharm, and is involved in [68 Ga]Ga-Pentixafor PET Imaging in PAN Cancer (FORPAN), sponsored and planned by PentixaPharm. Andreas K. Buck has received speaker honoraria from Novartis/AAA and PentixaPharm and is a member of the advisory board of PentixaPharm. All other authors declare no conflict of interest.